⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Since GLP-1 receptor agonists like Ozempic, Mounjaro, and Rybelsus entered mainstream awareness in India, they have attracted an enormous amount of misinformation — from social media, from well-meaning family members, from WhatsApp forwards, and sometimes even from healthcare providers not up to date on the evidence.
This guide addresses the most common myths circulating in Indian communities, with clear factual corrections based on published clinical trial data and regulatory guidance.
Consult your healthcare provider before starting any medication. This article is for informational purposes only.
FACT: GLP-1 receptor agonists were originally developed for type 2 diabetes, but semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are now approved in multiple countries for weight management in people without diabetes who have obesity or overweight with weight-related health conditions.
In India, the prescribing landscape is evolving. Many endocrinologists and physicians prescribe these medications for obesity, non-alcoholic fatty liver disease (NAFLD), polycystic ovarian syndrome (PCOS), and metabolic syndrome — all without a diabetes diagnosis.
The STEP 1 trial, which enrolled participants without diabetes, showed average weight loss of 14.9% over 68 weeks. The SURMOUNT-1 trial (tirzepatide) showed up to 22.5% average weight loss in non-diabetic patients with obesity.
If you have obesity or significant overweight with metabolic complications, speak with an endocrinologist — diabetes is not a prerequisite.
FACT: Obesity is a chronic medical condition with a powerful biological component. Research has established that losing weight triggers hormonal responses — particularly drops in leptin and rises in ghrelin — that drive hunger, slow metabolism, and actively resist weight maintenance. This is why most people regain weight after conventional dieting.
GLP-1 medications work by restoring signalling that is impaired in obesity. They reduce hunger, improve insulin sensitivity, and slow gastric emptying — correcting biological dysfunction, not bypassing effort.
A useful comparison: we do not consider blood pressure medication "cheating" at cardiovascular health, or insulin "cheating" at diabetes management. Treating a disease with appropriate medicine is not cheating — it is evidence-based care.
The patients doing best on GLP-1 medications are those who combine them with dietary changes and physical activity. The medication creates the window; the patient fills it with behaviour.
FACT: This is partially true but significantly overstated. Research does show that most people regain weight after stopping GLP-1 medications — the STEP 4 trial showed that participants who stopped semaglutide regained approximately two-thirds of lost weight over 52 weeks.
However, "immediately" is inaccurate. Weight regain is gradual, not overnight. And the degree of regain depends heavily on the lifestyle habits built during GLP-1 therapy.
The clinical reality:
Your doctor can help develop a stopping or tapering strategy if and when that becomes appropriate.
FACT: The thyroid cancer concern originates from rodent studies showing that high-dose GLP-1 receptor activation caused C-cell tumours (medullary thyroid carcinoma or MTC) in rats and mice — but at doses far exceeding human therapeutic ranges.
Critically, humans have far fewer GLP-1 receptors in thyroid C-cells than rodents. The FDA, EMA, and India's CDSCO have all reviewed this data and concluded that the rodent findings do not translate meaningfully to human risk at therapeutic doses.
Current evidence from long-term cardiovascular outcome trials (SUSTAIN, LEADER) — with hundreds of thousands of patient-years of follow-up — has not shown an increased rate of thyroid cancer in humans.
GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) — this is a precaution, not evidence that they cause thyroid cancer in the general population.
FACT: "Ozempic face" (facial volume loss and sagging skin) is a real but not inevitable consequence of rapid weight loss — not a direct drug effect. It occurs because aggressive caloric restriction depletes subcutaneous fat and can cause muscle loss, including in the face.
Prevention is possible and the evidence is clear:
Many patients on GLP-1 medications who maintain protein intake and exercise report minimal facial changes. It is a preventable side effect for the majority of people — not a foregone conclusion.
FACT: GLP-1 medications cause weight loss primarily through caloric reduction — but weight lost without exercise contains a significant proportion of lean muscle mass, not just fat.
The STEP 1 trial found that approximately 39% of weight lost on semaglutide without resistance exercise was lean mass — not fat. This has meaningful implications: muscle loss reduces metabolic rate, increases long-term weight regain risk, reduces strength and function, and increases the risk of what researchers call "metabolically obese normal weight" (sarcopenic obesity).
Exercise — particularly resistance training — while on GLP-1 medications:
GLP-1 medications make exercise easier by reducing appetite and improving energy. They are most effective when combined with physical activity, not used as a substitute for it.
FACT: The long-term safety data for GLP-1 receptor agonists is among the most robust of any modern class of metabolic medications:
These are not short-term studies. The SELECT trial enrolled over 17,000 participants and ran for 5 years. The medications have now been used by millions of patients worldwide for several years with comprehensive post-market surveillance data.
No long-term safety concern has emerged that was not identified in pre-approval trials. The medications appear to be significantly safer than the metabolic complications of untreated obesity.
FACT: This is one of the most dangerous myths circulating in India. Several "compounded semaglutide" products — sold through online pharmacies, WhatsApp groups, or informal medical channels at a fraction of the branded cost — are not equivalent to or safe substitutes for pharmaceutical-grade semaglutide or tirzepatide.
The problems with compounded or unverified versions:
In India, the only legally approved and quality-verified GLP-1 options as of 2025 are Ozempic (semaglutide, Novo Nordisk), Rybelsus (oral semaglutide, Novo Nordisk), and Mounjaro (tirzepatide, Eli Lilly) — all registered with CDSCO and available through legitimate pharmacy channels.
Purchasing from any other source carries significant safety risk. If cost is a barrier, discuss alternatives with your doctor — they may have guidance on patient assistance programs or approved generic options when they become available through regulatory channels.
FACT: This myth, which circulates heavily on Indian social media, is completely false. GLP-1 medications do not cause organs to shrink.
What does happen:
The liver fat reduction in NAFLD patients is actually a reason some hepatologists now advocate for GLP-1 medications in patients with liver disease.
FACT: Indian cuisine is diverse, and many traditional Indian foods are highly compatible with GLP-1 therapy. The challenge is real but manageable with thoughtful choices.
GLP-1 medications naturally reduce appetite for high-carbohydrate foods in many users — reducing the "pull" toward bread, rice, and sweets. Many Indian users spontaneously shift toward dals, lentils, paneer, eggs, and fish without being told to.
Traditional Indian protein sources — moong dal, masoor dal, rajma, chhole, paneer, eggs, chicken, and regional fish — are excellent on GLP-1. The adjustments needed are portion changes (less rice, more dal), not abandoning Indian food.
Regional cuisine like Kerala seafood, Tamil Nadu kuzhambu, Bengali mustard fish, Punjabi sarson saag with paneer, and Gujarati high-protein dals all work beautifully with GLP-1 therapy.
Myths aside, GLP-1 medications have real side effects and real contraindications that you should discuss with a qualified healthcare provider. These include:
The right conversation is with your endocrinologist or doctor — not a social media group, a relative who is also on GLP-1, or an online pharmacy.
Q: I heard GLP-1 medications cause depression and suicidal thoughts. Is this true?
The European Medicines Agency (EMA) reviewed the data in 2024 and found no causal link between GLP-1 medications and suicidality or depression. Many patients actually report improved mood as a result of weight loss and reduced food preoccupation. However, if you experience mood changes on any medication, report them to your doctor.
Q: Is it true that GLP-1 medications are only effective if you are very obese?
No. The medications show meaningful benefit across a range of BMI levels in the presence of metabolic complications. Benefit in lean Indians with insulin resistance (the "thin-fat" syndrome) is also being studied. Your eligibility should be determined by your doctor based on your complete metabolic picture.
Q: Can GLP-1 medications cause kidney failure?
No. Clinical evidence, including the FLOW trial (2024), actually shows that semaglutide reduces the progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. Kidney function should be monitored in patients with existing kidney disease, but GLP-1 medications are not nephrotoxic.
GLP-1 medications like Ozempic and Mounjaro are among the most thoroughly studied classes of drugs in the history of metabolic medicine. The myths surrounding them — on Indian social media, in families, and in some medical circles — are largely based on misunderstood rodent data, extrapolation from short-term anecdotes, or commercial misinformation.
The science is clear: these medications are effective, safe with appropriate medical oversight, and potentially life-changing for people with obesity and metabolic disease.
Make decisions based on evidence, and always in consultation with your healthcare provider.
Consult your healthcare provider before starting any medication.
